 LAS VEGAS, July 22, 2021 PRNewswire -- JanOne Inc. Nasdaq: JAN, a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has selected CPC Clinical Research CPC, a full-service academic research organization ARO, as manager for its upcoming Phase 2b clinical trial of lead product candidate JAN101 for treating Peripheral Artery Disease PAD. CPC will be responsible for the planning, organization, day-to-day execution, and management of the Companys study, and will collaborate with JanOnes appointed regulatory partner Avania, announced last month. 